sinc
demonstr
rna
interfer
rnai
mammalian
cell
consider
research
financi
effort
gone
toward
implement
rnai
viabl
therapeut
platform
rnai
without
doubt
promis
strategi
treatment
human
genet
disord
mani
target
propos
rnai
therapi
requir
chronic
treatment
research
agre
emphasi
must
place
safe
longterm
applic
rnai
drug
reap
benefit
last
rna
interfer
rnai
repres
power
versatil
gene
silenc
process
doublestrand
rna
dsrna
trigger
sequencespecif
cleavag
mrna
transcript
explos
research
follow
discoveri
caenorhabd
elegan
recent
result
rnaibas
protocol
analysi
gene
function
therapeut
applic
human
follow
pioneer
research
plant
nematod
rnai
demonstr
mammalian
cell
tuschl
colleagu
first
appli
short
interf
rna
sirna
guid
sequencespecif
suppress
gene
express
theori
everi
gene
amen
rnaibas
silenc
therefor
key
paper
led
surg
excit
among
research
medic
field
decad
quest
effici
rnai
therapeut
treat
wide
varieti
patholog
ongo
alreadi
made
remark
progress
must
emphas
improv
still
need
pave
way
rnai
develop
viabl
therapeut
approach
obvious
translat
rnai
broadli
applic
therapeut
platform
need
appropri
pharmaceut
consider
differ
level
clinic
drug
develop
eg
sirna
design
sirna
formul
straightforward
term
state
effici
deliveri
potent
sirna
expect
result
maxim
suppress
target
gene
extrapol
rnai
bench
bedsid
imper
consid
gene
knockdown
intens
also
dynam
gene
silenc
one
hand
precis
control
durat
rnai
gene
knockdown
provid
new
inform
complex
cellular
pathway
impli
interact
multipl
gene
without
reli
elabor
transgen
technolog
hand
therapeut
point
view
main
focu
review
may
relev
silenc
pathogen
gene
longer
period
time
improv
clinic
outcom
prolong
gene
silenc
effect
specif
sirna
formul
may
benefici
chronic
patient
adher
administr
frequenc
dose
schedul
could
significantli
scale
although
mani
vivo
studi
alreadi
highlight
enorm
therapeut
potenti
rnai
therapeut
strategi
recent
studi
shown
unintend
offtarget
effect
ote
activ
immun
inflammatori
pathway
perturb
endogen
cellular
pathway
small
dsrna
drug
especi
place
emphasi
longterm
treatment
chronic
diseas
toxic
issu
becom
increasingli
import
dealt
accordingli
present
data
avail
longterm
toxic
rnai
trigger
appropri
attent
paid
issu
context
prolong
rnai
silenc
review
primarili
focu
import
remark
strategi
light
prolong
rnai
gene
silenc
therapeut
purpos
differ
section
attempt
describ
sever
topic
avail
literatur
rnai
particular
relev
central
theme
review
sinc
discoveri
rnai
research
reveal
basic
step
rnai
pathway
mani
crucial
aspect
remain
unveil
rnai
effector
molecul
term
sirna
rna
duplex
nucleotid
nt
length
figur
small
rna
fragment
defin
product
longer
dsrna
process
rnase
iii
type
enzym
call
dicer
introduc
cell
cytoplasm
sirna
incorpor
protein
complex
term
risc
rna
induc
silenc
complex
contain
argonaut
endonucleas
one
strand
rna
duplex
retain
insid
risc
antisens
strand
guid
strand
subsequ
activ
risc
risc
use
guid
strand
bind
complementari
region
target
mrna
follow
transcript
cleavag
also
call
slice
opposit
phosphat
linkag
base
respect
end
guid
strand
cleavag
fragment
degrad
cellular
rnase
current
knowledg
rnai
pathway
suffici
recogn
intrins
gene
silenc
potenti
rnai
fact
sirna
employ
endogen
cellular
machineri
imper
regard
sirnaactiv
risc
risc
defin
multipleturnov
enzym
follow
michaelismenten
kinet
mrna
target
cleav
risc
recycl
rnai
pathway
identifi
destroy
mrna
impli
singl
enzym
complex
bind
cleav
multipl
mrna
transcript
moreov
risc
provid
addit
intracellular
stabil
sirna
guid
strand
protect
armada
singlestrandspecif
rnase
entrap
sirna
risc
catalyt
action
key
paramet
explain
inher
gene
silenc
effici
sirna
incorpor
risc
doublestrand
natur
make
resist
intracellular
degrad
contrast
singlestrand
rna
duplex
sirna
structur
advantag
better
protect
ubiquit
singlestrandspecif
nucleas
featur
make
duplex
sirna
significantli
stabl
intracellularli
alreadi
observ
short
time
scale
inher
stabil
also
taken
account
especi
compar
gene
silenc
effici
durat
sirna
unmodifi
antisens
oligonucleotid
latter
rapidli
degrad
cell
cytoplasm
effort
aim
improv
sirna
potenc
led
develop
longer
sirna
show
superior
silenc
effici
certain
target
site
compar
convent
direct
region
mrna
transcript
type
duplex
maxim
inhibit
longer
gene
silenc
persist
observ
concentr
lower
requir
convent
sirna
improv
rnai
silenc
thought
origin
recognit
cleavag
dicer
henc
annot
dicer
substrat
rna
disrna
could
facilit
incorpor
risc
figur
dicer
believ
particip
earli
step
risc
assembl
natur
hold
sever
exampl
conveni
rnai
amplif
mechan
exampl
nematod
plant
one
known
amplif
mechan
system
spread
rnai
silenc
effect
effect
attribut
dsrna
receptor
denot
c
elegan
respons
passiv
dsrna
transloc
cell
membran
intercellular
dsrna
transport
neighbour
cell
lack
gene
silenc
incub
mammalian
cell
nake
ie
unformul
sirna
make
like
mammalian
cell
type
normal
level
homologu
express
neglect
recent
studi
howev
conduct
wolfrum
et
al
reveal
least
partial
respons
vitro
hepatocellular
uptak
lipophil
sirna
incorpor
lipoprotein
complex
hdl
ldl
high
low
densiti
lipoprotein
respect
specif
rnai
silenc
express
cell
block
extracellular
epitop
antibodi
seem
decreas
cellular
intern
subsequ
silenc
effect
lipophil
sirna
target
apolipoprotein
b
apob
plant
fungi
worm
contain
endogen
rna
depend
rna
polymeras
rdrp
produc
secondari
dsrna
mrna
transcript
target
primari
sirna
result
dsrna
recogn
cleav
dicer
increas
intracellular
sirna
concentr
amplif
process
small
amount
initi
dsrna
lead
persist
gene
silenc
mammalian
cell
probabl
lack
rnadepend
polymeras
activ
one
must
reli
altern
strategi
achiev
prolong
gene
silenc
stabl
rnai
gene
silenc
sirna
mimick
dicer
cleavag
product
chemic
synthes
introduc
target
cell
figur
also
produc
intracellularli
short
hairpin
rna
shrna
precursor
continu
express
rnapolymerasedriven
express
cassett
figur
shrna
structur
function
relat
premicrorna
intermedi
biogenesi
endogen
encod
microrna
mirna
mirna
constitut
highli
conserv
class
small
rna
mediat
rnai
mainli
translat
inhibit
figur
illustr
first
step
product
mirna
occur
cell
nucleu
long
primari
transcript
call
primirna
express
endogen
genet
region
process
drosha
rnase
iii
enzym
nt
hairpin
imperfect
complementar
stem
precursor
mirna
premirna
shuttl
nucleu
cytoplasm
heterodim
complex
cytosol
dicer
process
premirna
matur
nt
mirna
duplex
interact
risc
modul
transcriptom
express
mammalian
mirna
tend
contain
mismatch
target
mrna
often
mediat
gene
silenc
translat
suppress
rather
transcript
slice
although
latter
also
describ
believ
bind
activ
mirisc
target
mrna
sequest
latter
translat
machineri
confin
cytoplasm
foci
call
process
bodi
p
bodi
therebi
prevent
protein
synthesi
analog
mirna
biogenesi
intracellular
process
shrna
origin
cell
nucleu
respons
nuclear
export
cytoplasm
shrna
cleav
dicer
yield
activ
sirna
correspond
dicer
substrat
rna
disrna
plasmid
vector
design
produc
shrna
nt
stem
nt
loop
higher
rnai
potenc
smaller
hairpin
rna
nt
stem
nt
loop
owe
improv
dicer
recognit
risc
incorpor
howev
recent
report
li
et
al
shown
context
nt
loop
shrna
nt
stem
outperform
longer
nt
shrna
explan
discrep
lie
abil
shrna
recogn
dicer
inde
wherea
shrna
nt
stem
nt
loop
bypass
dicer
cleavag
increas
loop
length
nt
also
turn
shrna
nt
stem
dicer
substrat
build
increas
understand
mirna
process
secondgener
shrna
develop
call
shrnamir
contrast
firstgener
shrna
elicit
structur
analog
premirna
shrnamir
transcrib
primirna
design
found
human
mirna
stem
replac
rna
sequenc
interest
advantag
shrnamir
shrna
lie
recognit
process
drosha
nucleoplasm
dicer
cytoplasm
lead
effici
intracellular
product
matur
sirna
increas
knockdown
effici
import
context
review
note
compar
synthet
sirna
induc
transient
knockdown
plasmid
vector
base
interfer
show
better
potenti
longterm
gene
silenc
establish
stabl
rnai
gene
silenc
cultur
cell
research
mostli
appeal
viral
express
vector
lentivir
vector
allow
genom
insert
shrna
express
transgen
adenovir
adenoassoci
viral
vector
aav
show
less
success
integr
viral
dna
remain
larg
episom
genom
integr
shrna
express
cassett
per
definit
result
stabl
rnaimedi
gene
silenc
target
gene
remain
silenc
long
transcript
sirna
precursor
proce
rnai
gene
therapi
approach
interest
studi
lossoffunct
phenotyp
follow
prolong
knockdown
target
gene
longterm
treatment
chronic
diseas
eg
viral
infect
hepat
b
hepat
c
therebi
eas
treatment
schedul
improv
patient
comfort
howev
clinic
set
use
synthet
sirna
transient
rnai
gene
silenc
may
advantag
continu
shrnasirna
product
dose
schedul
consequ
also
result
intracellular
sirna
concentr
therapeut
regimen
easili
adapt
relat
therapeut
need
addit
transgen
stabli
integr
host
genom
silenc
rapidli
histon
modif
hypermethyl
cpg
island
promot
region
instead
achiev
longterm
transgen
express
chromatin
silenc
result
gradual
extinct
transgen
activ
recent
grimm
colleagu
disclos
continu
express
high
intracellular
level
shrna
could
result
longterm
toxic
mice
observ
fatal
side
effect
primarili
ascrib
satur
lead
interfer
nuclear
export
mirna
precursor
mirna
function
possibl
solut
overcom
toxic
issu
lower
initi
viral
load
b
implement
vector
develop
induc
tissuespecif
promot
allow
feasibl
control
intracellular
shrna
concentr
overview
microrna
mirna
pathway
lead
modul
gene
express
translat
repress
primirna
primari
transcript
process
nucleoplasm
rnase
iii
enzym
drosha
result
premirna
shuttl
cytoplasm
recogn
cleav
dicer
form
matur
mirna
turn
mirna
incorpor
risc
retain
one
strand
probabl
help
helicas
therebi
allow
complex
bind
partial
complementari
region
mrna
believ
target
transcript
sequest
cytoplasm
foci
p
bodi
inaccess
translat
machineri
may
improv
activitytox
ratio
mous
model
hyperbilirubinemia
shown
adenovir
product
shrna
could
silenc
function
atpbind
cassett
multidrug
resist
protein
involv
liver
bilirubin
transport
three
week
effect
seem
correl
chang
level
endogen
precursor
mirna
nonetheless
strike
conclud
improv
rnai
gene
silenc
dsrna
toxic
flip
side
take
advantag
natur
mirna
pathway
earlier
stage
regard
synthet
sirna
function
downstream
rnai
pathway
better
safer
choic
bypass
dicer
cleavag
requir
nuclear
export
activ
synthet
sirna
employ
howev
vigil
still
requir
intracellular
excess
sirna
may
possibl
interfer
risc
avail
also
induc
competit
cellular
mirna
recent
report
describ
potent
specif
knockdown
hepatocytespecif
gene
mice
hamster
system
deliveri
lipidformul
sirna
also
demonstr
treatment
schedul
influenc
either
mirna
biogenesi
mirna
function
knowledg
mirna
expand
abl
better
assess
possibl
cellular
disturb
result
sirna
shrna
treatment
quantit
data
total
number
cellular
protein
molecul
involv
rnai
pathway
number
sirna
molecul
need
insid
cell
suffici
silenc
effect
could
help
toward
optim
sirna
therapi
without
aforement
toxic
issu
anoth
concern
rais
use
nonintegr
viral
vector
immunogen
especi
longterm
use
deem
necessari
eg
adenovirus
aav
furthermor
random
genom
insert
transgen
eg
integr
lentivir
vector
coincid
risk
hazard
vivo
viral
recombin
insert
mutagenesi
although
present
virus
still
effici
gene
deliveri
vector
combin
advers
effect
could
eventu
favour
nonvir
approach
meanwhil
nonvir
strategi
also
explor
extens
intracellular
shrna
product
sirna
express
plasmid
introduc
target
cell
complex
cation
lipid
polym
physic
method
like
electropor
microinject
unfortun
nuclear
import
plasmid
dna
pdna
vector
remain
predomin
bottleneck
gene
deliveri
process
therebi
give
prefer
synthet
sirna
function
mainli
cell
cytoplasm
nondivid
cell
especi
difficult
transfect
nonvir
vector
sinc
insuffici
amount
pdna
reach
nucleu
absenc
cell
divis
nuclear
barrier
temporarili
disassembl
although
gener
said
chemic
synthes
sirna
promis
therapeut
candid
treatment
variou
genet
patholog
vivo
druglik
properti
regard
unfavour
sirna
reach
desir
intracellular
locat
mani
extracellular
intracellular
barrier
overcom
figur
obvious
effici
sirna
bypass
obstacl
major
implic
extent
durat
gene
silenc
subsequ
determin
clinic
relev
dose
interv
sever
concept
strategi
propos
improv
sirna
pharmacokinet
eventu
therapeut
perform
extracellular
compart
focu
chemic
modif
sirna
formul
well
known
sirna
rapidli
degrad
extracellular
environ
nake
sirna
inject
intraven
recogn
cleav
rnase
type
nucleas
limit
serum
halflif
min
therefor
much
effort
undertaken
modifi
sirna
therapeut
chemic
order
reduc
suscept
serum
rnase
chemic
modif
includ
rna
backbon
modif
eg
phosphorothio
ps
boranophosph
ribos
modif
termin
modif
among
other
initi
concern
rais
regard
possibl
diminish
efficaci
chemic
modifi
sirna
owe
interfer
risc
incorpor
activ
recycl
sinc
howev
elabor
research
field
prove
chemic
modifi
sirna
also
effici
lower
mrna
level
sequencespecif
rnaidepend
pathway
modif
even
show
enhanc
gene
silenc
compar
unmodifi
counterpart
import
consider
make
whether
chemic
modif
aim
improv
extracellular
sirna
stabil
promis
light
prolong
knockdown
target
gene
one
could
expect
chemic
modifi
sirna
higher
bioavail
stay
intact
longer
period
time
blood
circul
therebi
also
improv
intens
durat
rnai
gene
silenc
effect
unexpectedli
layzer
et
al
abl
demonstr
stronger
silenc
persist
silenc
stabil
fluoro
pyrimidin
sirna
unmodifi
oh
sirna
hydrodynam
tail
vein
inject
probabl
suffici
high
concentr
sirna
reach
intracellular
target
site
hydrodynam
inject
exert
effect
nucleas
digest
becom
promin
contrast
find
modifi
sirna
duplex
target
hepat
b
viru
hbv
rna
ribos
oh
substitut
shown
effici
decreas
hbv
dna
hbv
surfac
antigen
serum
level
compar
nonmodifi
sirna
report
hydrodynam
inject
use
codeliv
sirna
replic
compet
hbv
vector
surprisingli
differ
activ
modifi
unmodifi
sirna
signific
highdos
level
almost
absent
lower
dose
vivo
sirna
degrad
nucleas
main
limit
factor
one
would
expect
observ
opposit
trend
also
indic
factor
increas
nucleas
resist
taken
account
work
chemic
modifi
sirna
besid
degrad
rnase
short
vivo
halflif
sirna
also
influenc
rapid
renal
clearanc
sinc
sirna
highli
hydrophil
neg
charg
phosphat
group
per
sirna
molecul
molecular
weight
kda
far
cutoff
glomerular
filtrat
kda
one
expect
renal
clearanc
emin
although
rnase
digest
slow
chemic
modifi
nucleic
acid
backbon
renal
clearanc
seem
ratelimit
factor
govern
vivo
halflif
sirna
chemic
modif
eg
phosphorothio
internucleotid
linkag
thio
ribonucleotid
increas
circulatori
halflif
sirna
promot
interact
serum
protein
conveni
strategi
modul
improv
sirna
biodistribut
dramat
alter
sirna
structur
conjug
small
molecular
weight
moieti
interest
exampl
coupl
sirna
heavychain
antibodi
fab
fragment
lipid
moieti
like
cholesterol
bile
acid
longchain
fatti
acid
lipophil
sirna
seem
incorpor
select
lipoprotein
particl
rich
phospholipid
cholesterol
mainli
hdl
ldl
lipophil
sirnalipoprotein
complex
abl
improv
sirna
biodistribut
evad
renal
clearanc
promot
cellular
uptak
hdl
ldl
lipoprotein
receptor
chimer
peptidesirna
complex
recent
shown
protect
mice
infect
japanes
enceph
viru
deliv
sirna
payload
brain
intraven
inject
intriguingli
major
sirnatr
mice
surviv
four
week
anim
control
group
die
within
day
rozema
et
al
recent
introduc
novel
polym
base
sirnaconjug
strategi
term
dynam
polyconjug
vivo
hepatocyt
target
conjug
nm
size
consist
revers
shield
membranedestabil
polyc
contain
cleavabl
target
ligand
sirna
link
intracellularli
reduc
disulfid
bond
effect
knockdown
two
endogen
hepat
gene
apob
peroxisom
prolifer
activ
receptor
alpha
ppara
demonstr
wildtyp
mice
follow
low
pressur
iv
inject
anoth
conveni
way
circumv
renal
clearanc
incorpor
sirna
gene
silenc
complex
larg
enough
evad
glomerular
filtrat
therebi
improv
sirna
pharmacokinet
biodistribut
pay
proper
atten
drug
discoveri
today
volum
number
novemb
overview
biolog
barrier
sirna
therapi
follow
intraven
iv
inject
vivo
applic
sirna
formul
nanos
carrier
fulfil
basic
requir
larg
enough
circumv
renal
clearanc
small
enough
abl
cross
capillari
endothelium
accumul
target
tissu
moreov
sirna
carrier
abl
evad
uptak
mononuclear
phagocyt
system
carrier
reach
target
cell
need
deliv
sirna
cytoplasm
usual
involv
cellular
uptak
endocytosi
follow
escap
endosom
carrier
disassembl
cytosol
ecm
extracellular
matrix
npc
nuclear
pore
complex
tg
transcript
gene
silenc
tion
packag
sirna
lead
construct
sirna
molecul
shield
circul
rnase
destabil
blood
compon
elimin
need
chemic
modif
mani
invent
sirna
formul
alreadi
shown
improv
vivo
potenc
sirna
dramat
textbook
case
underlin
import
sirna
formul
given
morrissey
et
al
administ
unformul
backbon
stabil
antihbv
sirna
hydrodynam
tail
vein
inject
effect
inhibit
hbv
replic
could
achiev
albeit
dramat
high
dose
regimen
three
daili
dose
mgkg
howev
formul
therapeut
sirna
stabl
nucleic
acid
lipid
particl
snalp
nm
size
investig
succeed
achiev
signific
longterm
reduct
hbv
activ
three
daili
inject
mgkgd
sirna
follow
weekli
administ
mainten
dose
six
week
recent
report
use
snalp
technolog
deliv
antiapob
sirna
cynomolgu
monkey
describ
mark
reduct
plasma
apob
protein
level
long
day
singl
iv
inject
mgkg
mark
davi
group
formul
sirna
cation
cyclodextrin
contain
polyc
cdp
equip
target
ligand
exampl
transferrin
deliveri
tumour
cell
overexpress
transferrin
receptor
system
deliveri
target
sirna
nanoparticl
twice
weekli
week
result
longterm
inhibit
tumour
cell
engraft
tumour
growth
murin
therapeut
model
metastat
ewe
sarcoma
interestingli
longterm
inhibit
observ
formul
surfac
modifi
transferrin
moieti
posit
outcom
demonstr
nontarget
formul
target
nanoparticl
deliveri
system
also
evalu
recent
nonhuman
primat
intracellular
compart
focu
chemic
modif
cellular
dilut
besid
improv
extracellular
level
also
intracellular
behaviour
chemic
modifi
sirna
may
play
pivot
part
improv
rnai
gene
silenc
potenc
durat
report
ascrib
prolong
gene
silenc
effect
cell
cultur
use
stabil
sirna
duplex
show
higher
resist
toward
nucleas
attack
suggest
intracellular
degrad
sirna
inde
partial
respons
transient
rnai
gene
silenc
interest
recent
report
takabatak
et
al
demonstr
depend
rnai
gene
silenc
durat
tissu
express
level
enhanc
nucleas
regard
type
sirnas
discov
c
elegan
mutant
preliminari
experi
egfp
transgen
rat
reveal
singl
administr
siegfp
kidney
result
reduct
egfp
express
two
week
transfect
siegfp
muscl
tissu
silenc
egfp
day
author
hypothes
higher
express
level
kidney
compar
muscl
could
respons
higher
intracellular
sirna
degrad
decreas
rnai
longev
propos
block
express
appli
sirna
result
sustain
gene
silenc
sirna
modifi
fluoro
pyrimidin
shown
increas
persist
luciferas
silenc
unmodifi
sirna
cell
transient
transfect
luciferas
report
vector
howev
assess
luciferas
silenc
type
modifi
sirna
cell
line
stabli
transfect
luciferas
report
gene
reveal
signific
differ
durat
gene
silenc
explain
layzer
et
al
tri
investig
gene
silenc
cell
cultur
longer
time
scale
prefer
approxim
vivo
condit
much
possibl
use
cell
cultur
model
stabli
express
transgen
interest
question
recent
whether
simultan
transfect
exogen
gene
sirna
suitabl
quantifi
rnai
fisher
et
al
investig
influenc
modest
altritol
sugar
modif
sirna
stabil
gene
silenc
persist
although
partial
modifi
sirna
show
increas
nucleas
resist
compar
wildtyp
sirna
author
observ
enhanc
durat
gene
silenc
result
durabl
suppress
pglycoprotein
express
data
underscor
fact
cellular
level
factor
mere
sirna
stabil
like
cellular
uptak
andor
recognit
rnai
machineri
taken
account
liao
wang
report
modif
serv
enhanc
sirna
lipophil
chemic
adjust
facilit
intracellular
sirna
penetr
improv
sirna
stabil
result
stronger
inhibit
insulinlik
growth
factor
receptor
express
rel
unmodifi
sirna
direct
target
sequenc
interestingli
seem
fast
divid
cell
line
gene
silenc
limit
intracellular
dilut
sirna
activ
risc
owe
cell
divis
result
vitro
gene
silenc
usual
last
day
slowli
divid
nondivid
cell
sirna
stabil
suppos
main
limit
factor
prolong
gene
silenc
intracellular
sirna
halflif
expect
shorter
cell
divis
time
intracellular
persist
activ
sirna
alreadi
shown
maintain
target
gene
inhibit
sever
week
differ
type
nondivid
primari
cell
paper
assum
stabil
rnai
effect
repres
physic
stabil
intracellular
sirna
trigger
unfortun
report
assumpt
experiment
evalu
song
et
al
perform
northern
blot
analysi
sirna
integr
suggest
intracellular
sirna
surviv
requir
activ
product
target
mrna
transcript
also
maliyekkel
et
al
report
stabl
gene
silenc
follow
transient
shrna
induct
growtharrest
noncycl
cell
howev
contrast
report
longlast
rnai
nondivid
cell
phenotyp
rnai
activ
coincid
intracellular
sirna
decay
analyz
rnase
protect
assay
two
possibl
explan
discrep
suggest
firstli
conceiv
rnai
phenotyp
mainli
govern
fraction
sirna
associ
risc
alreadi
mention
previous
expect
incorpor
guid
strand
risc
complex
provid
extra
protect
degrad
case
quantifi
total
intracellular
sirna
repres
effect
intracellular
rnai
potenti
secondli
propos
transcript
silenc
target
gene
could
held
respons
increas
silenc
durat
see
recent
vitro
vivo
data
nonmodifi
nucleasestabil
sirna
duplex
shown
evad
nucleas
attack
chemic
modifi
sirna
significantli
prolong
durat
gene
silenc
sirna
reach
cytosol
target
cell
contradictori
find
suppos
advantag
nucleasestabil
sirna
describ
section
unfortun
hinder
draw
clear
conclus
regard
nonetheless
although
benefit
nucleaseresist
sirna
insid
cell
cytoplasm
still
remain
question
chemic
modif
prove
use
approach
abrog
offtarget
effect
unwant
stimul
mammalian
immun
system
sever
nativ
sirna
sequenc
known
induc
tolllik
receptor
tlr
mediat
immun
respons
endosom
recognit
cytoplasm
receptor
pkr
dsrnabind
protein
kinas
receptor
rna
helicas
retino
acidinduc
genei
melanoma
differentiationassoci
consid
recogn
certain
structur
rna
characterist
nucleotid
sequenc
instanc
activ
uncap
triphosph
rna
bluntend
sirna
mitig
immun
respons
possibl
design
sirna
devoid
immunostimulatori
sequenc
motif
pay
proper
attent
dsrna
physic
structur
robust
approach
howev
select
incorpor
modifi
nucleotid
eg
ome
avoid
immun
receptor
activ
kleinman
et
al
show
recent
nt
longer
sirna
inhibit
choroid
neovascular
cnv
mice
sequenceindepend
targetindepend
manner
inhibit
result
cellsurfac
bind
gener
sirna
modifi
sirna
duplex
minim
activ
could
reduc
consequenti
undesir
effect
enhanc
target
specif
therefor
chemic
modif
certainli
help
optim
sirna
design
toward
minim
vivo
toxic
maxim
sirna
toler
major
report
literatur
deal
mammalian
rnai
gene
silenc
describ
sirnadirect
cleavag
destruct
cytoplasm
mrna
transcript
term
posttranscript
gene
silenc
ptg
although
first
believ
sirna
function
cell
cytoplasm
sever
report
studi
three
differ
sirna
function
cell
nucleu
rnai
transcript
gene
silenc
tg
antigen
rna
agrna
obtain
effect
transcript
level
sirna
molecul
need
taken
nucleu
exact
mechan
sirna
transport
nuclear
pore
complex
npc
still
need
clarifi
principl
sirna
molecul
small
enough
diffus
passiv
npc
reach
nucleoplasm
rnai
nuclear
function
demonstr
sirnamedi
degrad
snrna
abund
wellcharacter
rna
highli
defin
structur
specif
local
nucleu
furthermor
shown
sever
sirna
form
function
risc
nucleu
cleav
target
rna
high
effici
although
cite
report
describ
rnai
action
occur
cell
nucleu
still
encompass
ptg
process
essenti
basic
rule
appli
discuss
cytosol
rnai
see
section
tg
first
observ
doubli
transform
tobacco
plant
exhibit
suppress
phenotyp
transgen
caus
methyl
process
rnadepend
dna
methyl
rddm
seem
induc
rna
sequenc
ident
genom
promot
region
lead
tg
exact
molecular
mechan
rddm
unknown
like
involv
cytosin
methyl
histon
modif
chromatin
remodel
sever
recent
independ
report
also
show
induct
rddm
sirna
mammalian
cell
although
case
silenc
requir
simultan
use
multipl
sirna
sirnamedi
tg
mammalian
cell
appear
result
sirnadirect
histon
methyl
target
promot
although
subsequ
dna
methyl
also
observ
suppress
product
rang
virus
vitro
target
structur
accessori
gene
durat
ptg
effect
known
rather
limit
ie
vari
four
seven
day
prolong
silenc
day
achiev
use
adenoassoci
lentivir
vector
howev
efficaci
treatment
base
ptg
approach
potenti
limit
known
adapt
environment
pressur
rapid
select
sirna
escap
mutant
describ
vitro
reason
suzuki
et
al
made
use
tg
anoth
approach
prolong
suppress
effect
sirna
would
less
suscept
adapt
prolong
effect
expect
shown
regardless
exact
mechan
rddm
long
last
pass
across
gener
plant
system
c
elegan
absenc
origin
rnai
trigger
therefor
epigenet
modif
use
promoterspecif
sirna
could
interest
method
achiev
robust
gene
silenc
effect
although
suggest
probabl
need
constitut
express
promoterdirect
sirna
shrna
third
exampl
nuclear
sirna
function
impli
inhibit
gene
express
antigen
rna
agrna
complementari
transcript
start
site
within
human
chromosom
dna
contrast
tg
methyl
dna
requir
silenc
accompani
dimethyl
histon
agrna
treatment
shown
depend
activ
potent
inhibit
multipl
gene
suggest
agrna
may
repres
natur
mechan
control
transcript
valuabl
applic
silenc
gene
express
relat
silenc
process
prolong
gene
silenc
still
remain
unclear
addit
two
paper
recent
demonstr
synthet
agrna
could
also
potent
activ
gene
express
human
cancer
cell
line
present
suffici
evid
suggest
tg
could
appli
futur
therapeut
protocol
prolong
gene
silenc
desir
exact
mechan
tg
first
unravel
detail
abl
translat
gene
silenc
strategi
viabl
clinic
applic
broad
spectrum
variabl
paramet
defin
may
influenc
outcom
rnai
gene
silenc
knockdown
durat
paramet
situat
three
distinct
level
sirna
deliveri
formul
ii
intracellular
rnai
pathway
iii
envis
target
level
sirna
deliveri
one
must
keep
mind
vivo
tissu
distribut
pharmacokinet
sirna
formul
eg
sirna
contain
nanoparticl
major
impact
rnai
effect
target
cell
discuss
earlier
sirna
target
locat
intracellularli
biodistribut
extracellular
space
also
differ
step
intracellular
traffick
consid
import
process
like
cellular
uptak
mechan
confin
sirna
carrier
cytosol
vesicl
sirna
releas
carrier
influenc
rnai
effect
figur
exampl
sever
studi
shown
abil
sirna
sirna
carrier
complex
escap
endosom
compart
limit
step
gene
silenc
effici
obvious
rnaispecif
paramet
intracellular
sirna
stabil
risc
activ
sirnariscmrna
complex
kinet
account
import
risc
recycl
rnai
pathway
toward
sirna
gene
silenc
potenc
potenti
influenc
sirna
chemic
modif
emphas
earlier
last
least
turnov
intracellular
mrna
transcript
target
protein
stabil
care
consid
protein
halflif
extend
sever
day
even
effici
knockdown
intracellular
mrna
level
singl
sirna
dose
may
fail
alter
cellular
phenotyp
owe
residu
amount
stabl
protein
rate
cell
divis
imper
durat
gene
silenc
transient
rnai
approach
determin
transient
rnai
effect
realli
regard
target
cell
type
envis
therapeut
outcom
great
import
singl
administr
sirna
effect
block
tumour
cell
growth
inher
impli
prolong
effect
sinc
intracellular
sirna
dilut
due
cell
divis
disregard
detail
knowledg
impact
paramet
list
relat
rnai
gene
silenc
kinet
could
expedit
design
therapeut
sirna
strategi
predict
mathemat
model
illumin
key
factor
govern
durat
gene
silenc
could
help
instrument
setup
sirna
treatment
regimen
sever
report
describ
mathemat
equat
gain
insight
rnai
silenc
pathway
avail
literatur
raab
stephanopoulo
studi
impact
sirna
concentr
time
sirna
transfect
rel
report
plasmid
cotransfect
mous
hepatoma
cell
model
could
use
select
appropri
time
sirna
transfect
function
gene
induct
moment
analysi
use
takahashi
et
al
evalu
time
cours
endogen
protein
express
function
sirna
concentr
likewis
interest
report
arciero
et
al
describ
mathemat
model
tool
predict
tumourimmun
evas
studi
impact
sirna
administr
direct
immun
suppress
cytokin
tgfb
tumour
growth
bartlett
davi
first
construct
mathemat
model
incorpor
paramet
govern
vivo
sirna
deliveri
process
biodistribut
sirna
carrier
intracellular
traffick
vector
unpackag
endosom
escap
studi
kinet
sirnamedi
gene
silenc
model
calcul
also
appli
defin
dose
schedul
consist
repeat
sirna
inject
result
persist
gene
silenc
depend
halflif
target
protein
target
cell
divis
rate
illustr
exampl
nondivid
fibroblast
given
figur
author
employ
mathemat
model
sever
vitro
vivo
gene
silenc
studi
perform
target
sirna
nanoparticl
base
cation
cyclodextrin
provid
inform
could
aid
design
effect
sirna
deliveri
strategi
consid
differ
sirna
deliveri
strategi
also
note
could
interest
incorpor
deliveri
kinet
sirna
formul
predict
mathemat
model
amount
sirna
deliv
cytoplasm
function
time
determin
factor
toward
eventu
therapeut
outcom
intracellular
toxic
time
control
intracellular
releas
sirna
may
alway
better
sharpli
put
marsden
recent
edit
new
england
journal
medicin
regard
basic
toxicolog
paradigm
theori
everi
substanc
potenti
harm
exceed
certain
concentr
level
exposur
time
also
true
sirna
therapeut
judg
concentr
depend
advers
effect
offtarget
silenc
induct
immun
respons
satur
endogen
rnai
pathway
obvious
stress
imper
work
potent
sirna
design
lowest
concentr
possibl
keep
mind
one
overemphas
need
rigor
control
intracellular
sirnashrna
concentr
regul
number
activ
sirna
molecul
cell
cytosol
one
could
consid
use
condit
shrna
express
plasmid
express
cassett
deliv
target
cell
viral
nonvir
carrier
howev
regul
intracellular
sirna
concentr
becom
complex
case
nonvir
synthet
sirna
deliveri
mostli
electrostat
complex
sirna
cation
polym
polyplex
cation
lipid
lipoplex
appli
cell
polyplex
lipoplex
transient
rnai
effect
last
less
one
week
gener
observ
mani
formul
one
expect
upon
escap
endosom
provid
burst
releas
sirna
cytoplasm
releas
sirna
subsequ
prone
dilut
cell
divis
possibl
intracellular
degrad
lead
transient
gene
silenc
theori
timecontrol
releas
sirna
cell
cytoplasm
could
interest
maintain
intracellular
sirna
concentr
longer
period
time
minim
threshold
requir
effici
gene
silenc
without
flood
cell
cytoplasm
uncomplex
nake
sirna
control
amount
sirna
releas
cytosol
could
therefor
result
prolong
rnai
effect
achiev
goal
need
deliveri
vehicl
exhibit
tailor
timecontrol
sirna
deliveri
group
recent
publish
cation
biodegrad
polybamino
ester
pbae
abl
form
nanos
electrostat
complex
neg
charg
sirna
figur
follow
endocytosi
polyplex
hydrolyt
degrad
cation
polym
believ
increas
osmot
pressur
insid
endosom
vesicl
owe
accumul
degrad
product
exceed
crucial
pressur
threshold
eventu
lead
endosom
ruptur
hypothes
polym
degrad
rate
number
polyplex
resid
singl
endosom
govern
kinet
rise
osmot
pressur
endosom
membran
therefor
endosom
expect
ruptur
time
way
gradual
sirna
releas
cell
cytoplasm
expect
function
polym
degrad
therebi
alter
gene
silenc
kinet
figur
compar
approach
group
also
involv
design
biodegrad
sirna
impregn
gel
bead
microgel
drug
discoveri
today
volum
number
novemb
elicit
timecontrol
releas
incorpor
sirna
govern
hydrolysi
hydrogel
crosslink
depend
hydrogel
characterist
sirna
releas
time
tailor
hour
day
sever
week
gel
taken
target
cell
could
serv
intracellular
sirna
depot
slowli
disintegr
releas
entrap
sirna
owe
high
gene
silenc
potenti
sirna
small
number
activ
sirna
per
cell
sever
hundr
need
activ
veldhoen
et
al
provid
detail
quantit
analysi
cellularli
intern
sirna
liquid
hybrid
protocol
combin
data
observ
rnai
effect
reveal
half
maxim
silenc
sirna
molecul
necessari
case
cell
penetr
peptid
cpp
assist
transfect
requir
case
transfect
lipofectamin
tm
indic
amount
sirna
molecul
becom
avail
biolog
activ
may
depend
strongli
deliveri
agent
data
minim
number
sirna
molecul
need
trigger
suffici
rnai
effect
knowledg
kinet
rnai
effect
relat
intracellular
sirna
concentr
import
attempt
achiev
longterm
maxim
inhibitori
effect
emphas
number
crucial
paramet
need
consid
understand
rnai
gene
silenc
kinet
similarli
optim
control
sirna
releas
depend
cell
type
target
gene
instanc
clear
optim
sirna
releas
profil
achiev
sustain
gene
silenc
differ
significantli
slowli
divid
fast
divid
nondivid
cell
express
level
target
gene
also
greatli
influenc
amount
sirna
need
insid
cell
cytoplasm
maxim
gene
silenc
sirnasshrna
develop
target
viral
transcript
sequencespecif
manner
rnai
could
prove
next
best
thing
block
viral
replic
unfortun
mani
report
mention
drug
resist
induc
viral
mutagenesi
pressur
rnai
monotherapi
perplex
viral
genet
flexibl
could
also
entail
emerg
genet
encod
viral
rnai
suppressor
despit
great
potenti
rnai
antivir
therapi
issu
rais
complic
achiev
persist
viral
suppress
use
rnai
monotherapi
even
highli
activ
antiretrovir
therapi
haart
cocktail
three
antiretrovir
drug
use
erad
viral
replic
delay
diseas
progress
moreov
haart
notori
induct
sever
toxic
put
extra
barrier
effici
therapi
correl
haart
novel
rnai
approach
put
forward
call
combinatori
rnai
cornai
multiplex
approach
involv
concert
action
differ
sirna
shrna
effector
direct
multipl
viral
sequenc
although
major
antivir
rnai
studi
focu
target
viral
transcript
studi
also
devot
suppress
express
cellular
gene
key
import
viral
life
cycl
primari
goal
cornai
therefor
minim
emerg
viral
escap
mutant
order
maintain
longterm
antivir
effect
give
exampl
shown
respons
singl
shrna
inhibitor
mutat
insid
even
outsid
rnai
target
sequenc
provid
escap
rout
viru
eventu
nullifi
antivir
effect
combinatori
strategi
appli
multipl
shrna
express
singl
lentivir
vector
target
differ
region
genom
increas
viral
inhibitori
activ
seem
doubl
express
vector
also
provid
durabl
viral
inhibit
compar
observ
present
literatur
coxsackieviru
sarsassoci
coronaviru
clear
synergist
antivir
effect
obtain
combin
sirna
target
differ
function
gene
coronavir
genom
current
concept
cornai
also
includ
combin
rnai
trigger
nonrnaibas
suppressor
gene
express
even
antivir
protein
instanc
multiplex
strategi
result
longterm
inhibit
primari
cell
report
use
tripl
combin
antihiv
shrna
hammerhead
ribozym
target
hiv
coreceptor
chemokin
receptor
rna
decoy
hivtar
would
beyond
scope
review
discuss
plethora
report
avail
literatur
regard
combinatori
rnai
recent
excel
review
sole
devot
topic
publish
kay
grimm
would
like
refer
reader
review
refer
herein
comprehens
overview
differ
strategi
alreadi
explor
cornai
therapi
latter
paper
author
focu
mainli
antivir
potenti
cornai
nevertheless
rnai
regard
broad
therapeut
platform
addit
deploy
challengingtotreat
human
patholog
metabol
disord
cancer
combinatori
approach
could
therapeut
asset
context
achiev
longterm
silenc
recent
report
establish
synergist
effect
rnai
trigger
especi
combin
convent
low
molecular
weight
chemotherapeut
takei
et
al
employ
effect
sirna
midkin
mk
togeth
low
essenti
nontox
dose
paclitaxel
human
prostat
cancer
xenograft
found
paclitaxel
significantli
augment
antitumour
effect
mksirna
way
tumour
growth
inhibit
could
maintain
sever
week
without
need
switch
higher
probabl
toxic
dose
paclitaxel
unfortun
vivo
administr
sirnaatelocollagen
formul
use
report
restrict
intratumour
inject
synergist
phenomenon
howev
found
intraven
administr
target
nanoparticl
formul
antiegfr
sirna
combin
intraperiton
cisplatin
human
lung
cancer
xenograft
model
contrast
monotherapi
target
nanoparticl
contain
antiegfr
sirna
partial
reduc
tumour
growth
combin
target
sirnananoparticl
cisplatin
complet
inhibit
tumour
prolifer
week
third
earlier
report
describ
packag
sirna
neutral
liposom
vesicl
target
tyrosin
kinas
receptor
oncogen
overexpress
ovarian
cancer
liposom
sirna
administ
addit
paclitaxel
signific
reduct
tumour
growth
observ
compar
paclitaxel
combin
nonsilenc
sirna
neutral
liposom
formul
appli
target
focal
adhes
kinas
fak
synergist
effect
could
obtain
combin
therapeut
sirna
convent
chemotherapeut
docetaxel
cisplatin
altogeth
studi
cite
section
exemplifi
tremend
potenti
cornai
battl
variou
challeng
therapeut
target
human
diseas
particular
advantag
combin
differ
rnai
effector
without
altern
therapeut
maxim
silenc
effect
acut
longterm
needless
say
safeti
concern
rais
rnai
monotherapi
also
hold
true
cornai
multiplex
sever
sirnashrna
trigger
could
even
augment
risk
inher
link
rnai
offtarget
immunostimul
competit
endogen
mirna
follow
coadministr
differ
type
rnai
drug
even
compet
limit
amount
cellular
rnai
protein
therebi
diminish
efficaci
contrast
combin
rnai
effector
nonrnaibas
therapeut
may
allow
lower
dose
drug
way
cornai
still
profit
synergist
effect
along
benefit
reduc
toxic
advanc
biotechnolog
led
emerg
mani
macromolecular
drug
peptid
protein
nucleic
acid
research
tri
ever
sinc
improv
therapeut
outcom
new
spectrum
drug
use
differ
strategi
relat
drug
formul
need
deliv
drug
vivo
rna
interfer
advantag
abl
profit
lesson
learn
preclin
develop
antisens
oligonucleotid
aon
ribozym
sever
decad
research
aon
lead
expert
industri
academ
laboratori
still
acknowledg
invent
engin
strategi
improv
design
sirnasshrna
optim
vivo
deliveri
still
need
turn
therapeut
promis
rnai
clinic
realiti
clinic
applic
sirna
call
repeat
often
intraven
administr
desir
aim
durabl
effect
lengthen
treatment
interv
direct
applic
synthet
sirna
disadvantag
rnai
effect
transient
mainli
owe
intracellular
dilut
activ
sirna
depend
cell
divis
rate
maintain
suffici
silenc
target
gene
express
prolong
period
time
differ
strategi
propos
pay
proper
attent
practic
implic
eventu
lead
maxim
rnai
effect
term
magnitud
durat
sirna
duplex
design
modifi
optim
exploit
endogen
rnai
pathway
order
increas
gene
silenc
potenc
pursu
optim
sirna
design
lead
sirna
drug
candid
lower
ic
valu
enabl
effect
medic
treatment
lower
dose
incorpor
chemic
modifi
nucleotid
sirna
sequenc
proven
enhanc
halflif
bloodstream
protect
nucleas
activ
howev
conceiv
applic
nake
ie
unformul
nonconjug
sirna
mainli
limit
confin
target
site
local
administr
eye
respiratori
tract
advanc
materi
scienc
increas
chanc
design
new
nucleic
acid
deliveri
concept
nano
revolut
led
develop
intellig
nanodevic
enabl
extrapol
drug
deliveri
laboratori
real
vivo
situat
multifunct
deliveri
vehicl
sirna
conjug
strategi
offer
mani
advantag
system
applic
sirna
usual
equip
target
ligand
carri
stabil
hydrophil
polym
avoid
aggreg
bloodstream
prevent
nonspecif
uptak
reticuloendotheli
cell
moreov
deliveri
vehicl
often
modifi
improv
intracellular
traffick
eg
endosom
escap
lead
increas
intracellular
bioavail
includ
factor
carrier
design
enhanc
percentag
administ
sirna
dose
reach
target
site
system
deliveri
ultim
goal
defin
appropri
dose
schedul
given
sirna
formul
maintain
desir
therapeut
outcom
model
predict
aid
recogn
main
factor
govern
durat
sirna
effect
order
adjust
sirna
dose
frequenc
administr
accordingli
provid
research
gener
meaning
insight
system
sirna
deliveri
may
appli
varieti
sirna
carrier
depend
patholog
target
sustain
gene
silenc
readili
achiev
synthet
sirna
may
advis
purpos
research
seek
solac
intracellular
shrna
product
plasmid
viral
vector
although
much
progress
made
develop
viral
gene
therapi
vector
still
import
safeti
concern
remain
troublesom
moreov
littl
inform
avail
advers
effect
link
sustain
shrna
express
vivo
probabl
safe
longterm
applic
rnai
drug
requir
rigor
spatiotempor
control
intracellular
sirnashrna
concentr
smart
nanodevic
control
intracellular
sirna
deliveri
smart
plasmid
control
shrna
express
may
fulfil
necessari
requir
extra
inform
detail
box
